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Abstract
Background: In this study, we sought to determine the cellular source of inducible nitric oxide synthase (iNOS)
induced in lymphatic endothelial cells (LECs) in response to tumor necrosis factor (TNF), the effects of iNOS on
lymphatic smooth muscle cell (LSMC) function and on the development of arthritis in TNF-transgenic (TNF-Tg) mice,
and whether iNOS inhibitors improve lymphatic function and reduce joint destruction in inflammatory erosive arthritis.
Methods: We used quantitative polymerase chain reactions, immunohistochemistry, histology, and near-infrared
imaging to examine (1) iNOS expression in podoplanin + LECs and lymphatic vessels from wild-type (WT) and TNF-Tg
mice, (2) iNOS induction by TNF in WT LECs, (3) the effects of iNOS inhibitors on expression of functional muscle genes
in LSMCs, and (4) the effects of iNOS inhibitors on lymphatic vessel contraction and drainage, as well as the severity of
arthritis, in TNF-Tg mice.
Results: LECs from TNF-Tg mice had eight fold higher iNOS messenger RNA levels than WT cells, and iNOS expression
was confirmed immunohistochemically in podoplanin + LECs in lymphatic vessels from inflamed joints. TNF (0.1 ng/ml)
increased iNOS levels 40-fold in LECs. LSMCs cocultured with LECs pretreated with TNF had reduced expression of
functional muscle genes. This reduction was prevented by ferulic acid, which blocked nitric oxide production. Local
injection of L-N6-(1-iminoethyl)lysine 5-tetrazole-amide into inflamed paws of TNF-Tg mice resulted in recovery of
lymphatic vessel contractions and drainage. Treatment of TNF-Tg mice with ferulic acid reduced synovial inflammation
as well as cartilage and bone erosion, and it also restored lymphatic contraction and drainage.
Conclusions: iNOS is produced primarily by LECs in lymphatic vessel efferent from inflamed joints of TNF-Tg
mice in response to TNF and inhibits LSMC contraction and lymph drainage. Ferulic acid represents a
potential new therapy to restore lymphatic function and thus improve inflammatory arthritis by inhibiting local
production of nitric oxide by LSMCs.
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Background
The lymphatic system plays a critical role in mainten-
ance of fluid homeostasis and normal immune responses
[1]. It is also an important modulator of pathological
processes, such as inflammation, because it removes
harmful factors and cells from disease sites [2]. The im-
portance of lymph drainage in rheumatoid arthritis (RA)
has been established in studies demonstrating that (1)
lymph efferent from inflamed joints contains high levels
of cytokines and chemokines [3], (2) synovial specimens
from patients with RA and mice with inflammatory
erosive arthritis have increased numbers of lymphatic
vessels [4–6], and (3) the size of draining lymph nodes is
a biomarker of arthritic flare [7–9]. Additional preclin-
ical studies using the tumor necrosis factor–transgenic
(TNF-Tg) [10] and K/B × N [11] mouse models of
chronic inflammatory erosive arthritis have also revealed
defects in lymphatic drainage in these models (recently
reviewed [12]). In summary, longitudinal in vivo imaging
and cell labeling studies have demonstrated that arthritis
progression commences with decreased lymphatic
clearance [8, 13], which is associated with dysfunction of
collecting lymphatic vessels draining affected joints,
including reduced or absent contractility [14] and
decreased pumping pressure [15]. However, the cellular
and molecular mechanisms responsible for impaired
lymphatic function during arthritis progression are not
fully understood.
The lymphatic vasculature is composed of capillaries
and collecting vessels that have different morphology,
structural composition, and function [1]. For example,
lymphatic capillaries consist of a single layer of lymph-
atic endothelial cells (LECs), which are phenotypically
characterized by surface expression of lymphatic vessel
endothelial hyaluronan receptor 1 (LYVE-1), podoplanin
(PDPN), or CD31 [2]. Collecting lymphatic vessels have
valves that maintain unidirectional flow and are covered
by lymphatic smooth muscle cells (LSMCs) that express
α-smooth muscle actin (SMα) [16, 17]. Unlike the car-
diovascular system, the lymphatic system has no central
pump. Thus, lymph movement is achieved by alternating
contraction and relaxation of LSMCs that propels lymph
through valves to upstream draining lymph nodes and
eventually to the venous circulation [18, 19]. Mechanical
compression during contractions of adjacent skeletal
muscle and changes in pressure in arteries also promote
lymph transport along the collecting vessels [18, 19].
Therefore, an emerging theory of impaired function in
lymphatic vessel efferent from arthritic joints during
chronic systemic inflammation in RA is that there is a
breakdown in the function of their LECs and/or LSMCs
that results in afferent synovitis due to decreased lymph
egress from affected joints [9, 12]. Initially, this breakdown
involves loss of efferent lymphatic vessel contractions via
undefined mechanisms, which leads to LEC and LSMC
damage, apoptosis, and extensive lymphatic vessel de-
struction by inflammatory cells that become resident due
to the absence of lymph flow [12]. Thus, elucidating the
mechanisms responsible for the loss of lymphatic contrac-
tions and developing interventions to restore efferent
lymph flow from arthritic joints are important frontiers in
RA research and drug development.
Nitric oxide (NO) is a primary regulator of lymphatic
vessel contraction via its vasodilatory signal in LSMCs
[20, 21]. In a mouse model of acute inflammation,
contraction of LSMCs is attenuated by excessive NO
produced by inducible nitric oxide synthase (iNOS)-ex-
pressing CD11b+Gr-1+ myeloid cells [22]. Most recently,
Scallan and Davis used an elegant ex vivo model to dem-
onstrate that genetic removal of basal NO enhances con-
tractile activity in isolated murine collecting lymphatic
vessels [23]. Several studies have also demonstrated NO
and iNOS involvement in inflammatory arthritis, includ-
ing increased circulating NO levels in serum, urine, and
synovial fluid of patients with RA [24, 25], as well as
higher iNOS levels in synovial tissues of RA joints than
in osteoarthritic joints and absence of iNOS in normal
joints [26–29]. In addition, LECs can be induced with
lipopolysaccharide in culture to express iNOS [30], NOS
inhibitors reduce synovial inflammation and tissue dam-
age in arthritic rats [31], and increased NO production
in LECs causes impairment of lymphatic drainage in cir-
rhotic rats [32]. However, the factors regulating iNOS
expression in lymphatic vessels efferent from inflamed
joints and the effects of iNOS on lymph drainage during
the development of inflammatory erosive arthritis have
not been investigated. In the present study, we used
TNF-Tg mice to identify the cellular source of iNOS
expression in efferent lymphatic vessels from inflamed
joints, the role of LEC-produced iNOS in inhibition of
LSMC function, and the effects of NO inhibitors (Nω-
nitro-L-arginine methyl ester [L-NAME] and L-N6-(1-
iminoethyl)lysine 5-tetrazole-amide [L-NIL]), as well
as ferulic acid (FLA; the active component of an herbal
therapy for RA [33, 34]), on LEC-mediated LSMC inhib-
ition, lymphatic dysfunction, and joint pathology. We
provide the first evidence that LECs produce iNOS and
that the resulting NO inhibits LSMC function. Further-
more, selective iNOS inhibitors restore LSMC function
and lymph flow from affected joints and prevent inflam-
matory erosive arthritis in mice.
Methods
Animals
All murine studies were performed according to protocols
approved by the University of Rochester Committee on
Animal Resources. The 3647 line of TNF-Tg mice was
generated by Dr. George Kollias (Institute of Immunology,
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Alexander Fleming Biomedical Sciences Research Center,
Vari, Greece) [10]. The TNF-Tg mice were bred as hetero-
zygotes on a C57BL/6 background, and their wild-type
(WT) littermates were used as healthy controls. These
TNF-Tg mice have normal ankle joints at age 1 month,
display mild ankle joint inflammation and bone erosion at
2–2.5 months of age, and have severe erosive arthritis
at >5 months of age [35, 36]. Primary LSMCs were
generated from 1- to 2-month-old Sprague-Dawley rats
that were purchased from Shanghai Laboratory Animal
Center (Shanghai, China). These studies were conducted
in adherence to the Guiding Principles for the Care and
Use of Laboratory Animals according to the Regulations
of the People’s Republic of China for Administration of
Laboratory Animals. In vivo drug treatments were per-
formed as follows. To evaluate the immediate effects of
the iNOS inhibitor L-NIL (CAS 159190-45-1; Cayman
Chemical, Ann Arbor, MI, USA), mice were anesthetized
with approximately 2 % vol/vol isoflurane in oxygen, and
indocyanine green (ICG) was injected into their footpads
and visualized using near-infrared (NIR) imaging. Thirty
minutes later, 0.1 ml (4 mg/kg) of L-NIL or saline was
injected into footpads during the NIR-ICG imaging ses-
sion. The lymphatic pulse and clearance were monitored
by NIR-ICG imaging after treatment. The effects of long-
term NO inhibition were assessed by adding 100 ng/ml of
L-NIL or 100 ng/ml of the general NOS inhibitor L-
NAME (CAS 51298-62-5; Cayman Chemical) to the drink-
ing water, which was changed every day for 6 weeks. Feru-
lic acid (CAS 1135-24-6; Shanghai Forever Biotech Co.,
Ltd, Shanghai, China) was dissolved in saline. Mice were
gavaged daily with ferulic acid solution (20 mg/kg/day) or
saline for 12 weeks. We determined that the purity of
ferulic acid was more than 98 % by high-performance
liquid chromatography (Additional file 1).
Immunohistochemistry
Immunohistochemistry (IHC) was performed on frozen
sections of fresh popliteal lymph nodes (PLNs) and limb
tissues containing lymphatic vessels obtained from the
mice, as described previously [37]. Tissues were frozen in
Tissue-Tek® O.C.T compound (Sakura Finetek, Torrance,
CA, USA). To assist with identification of lymphatic
vessels between the paws and PLNs, 0.5 % Evans Blue dye
was injected into footpads 5 minutes before the animals
were killed and tissues were dissected. Sections (6 μm
thick) were cut from blocks containing PLNs and lymph-
atic vessels using the CryoJane Tape Transfer System
(Leica Biosystems, Wetzlar, Germany). Before staining,
slides were exposed to room temperature (RT) for at least
30 minutes. The sections were fixed in 4 % paraformalde-
hyde for 10 minutes at RT or in acetone/ethanol for 5 -
minutes at −20 °C, followed by washing with phosphate-
buffered saline (PBS) three times for 5 minutes each. A
blocking buffer (3 % bovine serum albumin [BSA] in PBS)
was applied for 30 minutes at RT. Fluorescence-
conjugated antibodies, including mouse anti-LYVE-1
Alexa Fluor 488 (eBioscience, San Diego, CA, USA),
mouse anti-iNOS/NOS type II fluorescein isothiocyanate
(FITC; BD Biosciences, San Jose, CA, USA), antimouse
Gr-1 phycoerythrin (PE) (eBioscience), and hamster
antimouse PDPN (Abcam, Cambridge, MA, USA), were
diluted in blocking buffer and incubated with sections over-
night at 4 °C. After being washed with 0.1 % PBS with
Tween 20 three times, the sections were mounted with
Molecular Probes ProLong Gold antifade reagent and 4′, 6-
diamidino-2-phenylindole (DAPI; Life Technologies, Carls-
bad, CA, USA). Images were taken under a Zeiss Axio
Imager (Carl Zeiss Microscopy, Oberkochen, Germany)
and analyzed by AxioVision Rel (Carl Zeiss Microscopy).
Flow cytometry and purification of synovial lymphatic
endothelial cells
Soft tissue and muscles were removed from entire legs
and digested with 2 ml of 1 mg/ml collagenase I
(Worthington Biochemical, Lakewood, NJ, USA) for 1 h
at 37 °C. Digestion was terminated by adding 8 ml of 2 %
fetal bovine serum (FBS) in PBS and filtered with a 40-μm
Falcon cell strainer (Corning, Corning, NY, USA). Centri-
fuged cells were washed twice with MACS buffer (0.5 %
BSA, 2 mM ethylenediaminetetraacetic acid [EDTA] in
PBS, pH 7.2), recentrifuged, and resuspended with 95 μl
of MACS buffer plus 5 μl of PE-conjugated anti-PDPN
antibody (catalog number 127407, lot B164982; BioLe-
gend, San Diego, CA, USA) for 30 minutes at 4 °C, and
then with 95 μl of MACS buffer plus 5 μl of anti-PE
microbeads (catalog number 130-048-801; Miltenyi Bio-
tec, Auburn, CA, USA) for another 30 minutes at 4 °C.
Cells were resuspended with 0.5 ml of MACS buffer and
passed through an LS separation column (catalog number
130-42-401; Miltenyi Biotec). After extensive washing,
PDPN+ cells were collected from the LS column by
flushing with 0.5 ml of MACS buffer. About 20,000
cells were obtained per mouse leg. To characterize
PDPN+ cells as LECs, cells were stained with goat anti-
mouse vascular endothelial growth factor receptor 3 anti-
body (catalog number AF743, lot DAB0231021; R&D
Systems, Minneapolis, MN, USA) followed by Alexa Fluor
488–conjugated antigoat immunoglobulin G secondary
antibody (catalog number A11078, lot 1613914; Life Tech-
nologies), or with biotin-conjugated mouse LYVE-1 (cata-
log number 13-0443-80; eBioscience) followed by
allophycocyanin-conjugated streptavidin (catalog number
17-4317-82, lot E07261-169; eBioscience), or PE-
conjugated mouse PDPN antibody, and subjected to flow
cytometry (BD LSR II 12-color flow cytometer; BD Biosci-
ences). The data were analyzed with FlowJo software (ver-
sion 7.6.5; FlowJo, Ashland, OR, USA).
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Real-time polymerase chain reaction
RNA was extracted from LECs and LSMCs using TRIzol
reagent (Life Technologies), and complementary DNA
was prepared from total RNA using the GeneAmp RNA
PCR Core Kit (Applied Biosystems, Foster City, CA,
USA). Quantitative polymerase chain reaction (PCR) amp-
lification was performed in triplicate with gene-specific
primers and iQ SYBR Green Supermix (both from Bio-
Rad Laboratories, Hercules, CA, USA) in an iCycler real-
time PCR machine (Bio-Rad Laboratories). The relative
abundance of each gene was calculated by subtracting the
threshold cycle (Ct) value of each sample for an individual
gene from the corresponding Ct value of β-actin (ΔCt).
The ΔΔCt value was obtained by subtracting the ΔCt of
the test samples from the ΔCt of control samples. These
values were then raised to the power of 2 (2−ΔΔCt) to yield
the fold expression relative to the reference level. The
expression levels of functional muscle genes were exam-
ined using sequence-specific primers, which are listed in
Additional file 2.
Western blot analysis
Whole-cell lysate samples were fractionated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes (20 μg of protein/
lane). Immunoblotting was carried out using antibodies to
smooth muscle myosin heavy chain 2 ([sMYH2] catalog
number ab53219, lot GR162408-3; Abcam), h1-calponin
([h1-Cal] catalog number C2687, lot 052 M4849; Sigma-
Aldrich, St. Louis, MO, USA), SMα22) (catalog number
ab14106, lot SR103317-2; Abcam), nuclear factor κB2
([NF-κB2] catalog number 8242, lot 1; Cell Signaling
Technology, Danvers, MA, USA) at 1:1000 dilution, iNOS
(catalog number ab3523, lot GR187485-2; Abcam) at
1:800 dilution, and β-actin (catalog number A2228, lot
052M4816V; Sigma-Aldrich) at 1:5000 dilution. Bands
were visualized using enhanced chemiluminescence
(Amersham, Little Chalfont, UK). Signal intensity of bands
was measured by densitometry.
Nitric oxide levels
LECs were seeded at 106/well in six-well plates over-
night, pretreated with 1 μM aminoguanidine hemisulfate
salt (Ami) and FLA (250 μM) for 3 h, and then with
1 ng/ml TNF for 24 h. Supernatants were collected, and
nitrite levels were assessed using an NO assay kit (cata-
log number A012; Nanjing Jian Cheng Bioengineering
Institute, Nanjing, China). This kit transforms nitrate to
nitrite via nitrate reductase first, and then uses Griess
reagent to detect the total amount of nitrite, from which
the total NO levels are calculated. It does not detect
reactive oxygen species [38].
Isolation of lymphatic smooth muscle cells
We followed a published protocol for isolating LSMCs [39].
Mesenteric lymphatic vessels from 1- to 2-month-old rats
were identified by injecting 10 μl of 0.5 % Evans blue dye
into the mesenteric lymph nodes. Blue-stained lymphatic
vessels that were easily separated from blood vessels were
harvested, cut into small pieces, and transferred to a 1 %
gelatin-coated plastic tissue culture dish. We used rats for
these isolations because it is impossible to isolate LSMCs
from mouse mesenteric lymphatics, owing to their much
smaller size and difficulty in separating lymphatic from
blood regular vessels. Cells were cultured in high-glucose
Dulbecco’s modified Eagle’s medium supplemented with
20 % FBS, 2 mM sodium pyruvate, 2 mML-glutamine, and
antibiotics. The culture medium was changed every 3 days.
Smooth muscle cells covering lymphatic vessels migrated
from the vessels after 3–4 days, and vessel segments were
removed aseptically. The cells were trypsinized after 7–10
days with 0.25 % trypsin in 0.02 % EDTA and transferred to
a new gel-coated dish (passage 0). After 1–2 weeks, the cells
reached confluence and were split into two dishes (passage
1). The cells were fixed with 10 % formalin for 10 minutes,
blocked with 0.2 % Triton-100 and 1 % BSA in PBS for
30 minutes at RT, stained with FITC anti-αSMA antibody
(1:400) at 4 °C overnight, and observed under a fluorescence
microscope (Olympus IX 71; Olympus America, Center
Valley, PA, USA). Whole-cell lysates were examined by
Western blot analysis using a 1:1000 dilution of an anti-
sMYH antibody (catalog number ab53219, lot GR162408-3;
Abcam) and a 1:5000 dilution of anti-β-actin antibody (cata-
log number A2228, lot 052M4816V; Sigma-Aldrich).
Coculture of LECs and LSMCs
A murine LEC cell line established from Freund’s adju-
vant–induced benign lymphangiomas [40] (cells provided
by Dr. S. Ran from the University of Illinois, Springfield,
Illinois, USA) was seeded on ten coverslips (15 mm×
0.25 mm thick) at 106 cells/coverslip in a 10-cm dish.
After 2 days, LECs were treated with 1 ng/ml TNF (cata-
log number 510-RT-010; R&D Systems) with or without a
selective iNOS inhibitor (1 μM Ami, catalog number
M7033; Sigma-Aldrich) for 24 h. Coverslips with LECs
were then transferred into another 10-cm dish, which had
already been coated with 2 × 105 LSMCs for 4 days. After
24 h of coculture, coverslips with LECs were removed and
LSMCs were harvested for analysis.
Near-infrared indocyanine green lymphatic imaging
NIR-ICG lymphatic imaging was performed as described
previously [13, 37]. In brief, fur was removed from
mouse legs with a depilatory cream (Veet; Reckitt
Benckiser, Slough, UK). A 6-μl solution of ICG in
distilled water (0.1 mg/ml) was injected intradermally
into footpads. As shown in Figs. 3 and 4, ICG signaling
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was measured using a custom-made NIR-ICG system in
which the ICG fluorescence is excited with light from a
tungsten halogen bulb with a nondichroic, parabolic
reflector to enhance NIR output and passed through a nar-
row excitation filter (part number ICG-B; Semrock, Roches-
ter, NY, USA). As shown in Fig. 5, the ICG signal was
measured using a Fluobeam 800 system (Fluoptics, Gre-
noble, France) that is composed of an electrical box contain-
ing the laser, laser power supply, an analogical/numerical
module and light-emitting diode (LED) power supply, and
an optical head containing the charge-coupled device cam-
era and the LED lamps. The imaging system was controlled
using Fluobeam software (V3.0; Fluoptics). NIR fluorescence
of the entire leg was recorded for 1 h to observe efferent col-
lecting lymphatic vessels from the ankle, including joints,
synovium, and surrounding soft tissue. Recording sessions
were repeated at 6 and 24 h for comparison with recordings
from the first 5 minutes after injection. Using ImageJ soft-
ware (National Institutes of Health, Bethesda, MD, USA),
regions of interest (ROIs) were identified in the footpad and
collecting lymphatic vessels to estimate (1) percentage
clearance from the footpad ROI at 1 h or 6 h and
24 h after ICG injection and (2) vessel contraction
rate, based on events exceeding an ROI fluorescence
intensity threshold 400 seconds after injection, as we
described previously [13, 37].
Histologic and histomorphometric analyses
Ankle joints were fixed in 10 % phosphate-buffered forma-
lin, decalcified in 10 % EDTA for 21 days, and embedded
in paraffin. A series of 4-μm-thick sections was cut, and a
total of ten sections were collected and divided into three
levels. Each level was 40 μm from the previous level. One
section from each of the three levels was stained with
Alcian Blue/Orange G or for tartrate-resistant acid phos-
phatase (TRAP) activity to identify osteoclasts. Sections of
the entire ankle joint, including the distal tibia and prox-
imal metatarsal bones, were digitized using an Olympus
VS120-S5-E whole-slide imaging system (Olympus
America). All images were analyzed using Olympus Oly-
VIA software (Olympus America). We outlined ROIs,
which included distal tibia, talus, calcaneus, proximal
metatarsal bone, synovial capsules, ligaments, and
adjacent soft tissues. The total tissue area of the ROI was
determined automatically with Olympus VS120 software
and ranged from 3.77 mm2 to 4.89 mm2. The area of in-
flammation and bone area were expressed as a percentage
of the total tissue area. The area of TRAP+ cells and cartil-
age area were expressed in square millimeters. The data
are presented as the means from three levels.
Statistical analysis
Data are presented as means ± standard deviations. Stat-
istical analyses were performed with SPSS 16.0 software
(SPSS, Chicago, IL, USA). Differences between two groups
were compared using Student’s t test. One-way analysis of
variance test followed by a Bonferroni-corrected posttest
was used for comparisons of more than two groups. p
Values <0.05 were considered statistically significant.
Results
iNOS induced by TNF in LECs results in NO inhibition of
LSMC gene expression
To define the cellular source of iNOS in efferent lymphatic
vessels from affected joints in TNF-Tg mice, we performed
multicolor fluorescence IHC on PLNs and lymphatic
vessels draining the ankle [41]. Consistent with reports
based on other murine models of inflammation [22], we
found large numbers of iNOS-expressing Gr-1+ myeloid
cells within LYVE-1+ lymphatic vessels in the PLNs
(Additional file 3). However, because it is unlikely that NO
from these cells could affect LSMC contractions in the
absence of an LEC barrier defect, we tested the hypothesis
that LECs are a primary source of iNOS. We found that in
vitro purified PDPN+ LECs from TNF-Tg mouse synovium
have a significant 8-fold higher iNOS mRNA expression
level than WT LECs (Fig. 1a and b) and that TNF
(≥0.1 ng/ml) stimulation of WT LECs significantly in-
creased iNOS levels by 40-fold (Fig. 1c). IHC confirmed
that PDPN+ LECs in efferent lymphatic vessels from
arthritic ankles from TNF-Tg mice express iNOS (Fig. 1d).
To determine if TNF-Tg LECs affect LSMC function
in vitro, we established a coculture system by treating
LECs with TNF, coculturing the stimulated LECs with
LSMCs, and then examining muscle-related gene expres-
sion in the LSMCs (Fig. 2a). We found that paracrine fac-
tors from the TNF-stimulated LECs significantly reduced
expression of multiple functional muscle genes, including
h1-Cal, smooth muscle myosin heavy chain 11, SMα2, and
SMα22 (Fig. 2b). These inhibitory effects appeared to be
NO-dependent because addition of the iNOS inhibitor
Ami to the cocultures fully restored LSMC gene expression
(Fig. 2c) and returned NO levels to baseline (Fig. 2d). Inter-
estingly, TNF stimulation did not affect SMα1 mRNA level,
which we subsequently used as an LSMC-specific gene
control together with a non–cell-specific NF-κB2 control.
Selective iNOS inhibition partially restores lymphatic
vessel contractions and lymph drainage in TNF-Tg mice
with severe arthritis
We have shown previously that TNF-Tg mice with severe
arthritis typically have reduced or loss of lymphatic
vessel contractions and decreased lymphatic flow from
inflamed joints, but the mechanisms involved are un-
known [7, 8, 13, 37]. To elucidate these mechanisms,
we first determined the initial onset of lymphatic dys-
function in the hind limbs of TNF-Tg mice using lon-
gitudinal NIR-ICG imaging (Fig. 3). We found a
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significant delay in ICG clearance from the footpads
of TNF-Tg mice beginning approximately 2.5 months
of age, as compared with their WT littermates. To as-
sess the role of iNOS in these changes in the lower
limbs of TNF-Tg mice with ankle arthritis, we exam-
ined the acute effects of local administration of the
selective iNOS inhibitor L-NIL (Fig. 4a and b) and
found that a single injection of L-NIL increased
lymphatic flow and partially restored lymphatic
contractions within 400 seconds of administration,
while injection of saline had no effects.
To confirm that lymphatic function recovery was due
to iNOS inhibition and to assess drug effects on normal
lymphatic vessel function, we treated cohorts of TNF-Tg
mice with severe ankle arthritis and their WT littermates
with saline, L-NIL, and the nonspecific NOS inhibitor L-
NAME for 6 weeks (Fig. 4c and Additional file 4). Unfor-












































































Fig. 1 Lymphatic endothelial cells (LECs) in efferent vessels from arthritic paws of tumor necrosis factor–transgenic (TNF-Tg) mice express high
levels of inducible nitric oxide synthase (iNOS). a Podoplanin-positive (PDPN+) LECs were isolated from joints of 7-month-old TNF-Tg mice and
their wild-type (WT) littermates using phycoerythrin (PE) anti-PDPN antibody/anti-PE microbeads passed through an LS column. Cells were subjected
to flow cytometry to assess their surface expression of LEC markers. b The expression levels of TNF, endothelial nitric oxide synthase (eNOS), and iNOS
in LECs were determined by quantitative polymerase chain reaction (qPCR). The fold changes normalized to actin were calculated using a WT sample
value as 1. Values are mean ± SD of five mice. c A murine LEC line was treated with different concentrations of TNF for 24 h. The expression levels of
TNF, eNOS, and iNOS were determined by qPCR. The fold changes were calculated using phosphate-buffered saline (PBS)-treated sample values as 1.
Values are mean ± SD of three samples. *p < 0.05 vs. PBS-treated samples. The expression levels of iNOS protein were determined by Western blot
analysis. d Collecting lymphatic vessels and surrounding tissues were harvested from TNF-Tg mice older than 5 months of age. Frozen sections were
stained with hematoxylin and eosin (H&E) or double–immunofluorescence-stained with anti-PDPN for LECs and anti-iNOS antibodies. H&E-stained
section (a) shows a lymphatic vessel with an open lumen (indicated by blue arrows). Immunohistochemically stained sections show (b) PDPN+ lymphatic
vessel endothelium (red), (c) iNOS+ vessels (green), and (d) merged PDPN+/iNOS+ LECs (yellow). Bar represents 200 μm. mRNA messenger RNA, LYVE-1
lymphatic vessel endothelial hyaluronan receptor 1, VEGFR3 vascular endothelial growth factor receptor 3
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toxic for assessment of lymphatic function, with a >50 %
fatality rate in the L-NAME group and a >30 % fatality
rate in the L-NIL group beyond 6 weeks of treatment.
However, NIR-ICG imaging at 6 weeks posttreatment
demonstrated that L-NIL significantly increased the
lymphatic pulse in TNF-Tg mice (from 0.42 ± 0.84 to
2.19 ± 0.77 pulses/minute; p < 0.05), but not in their
WT littermates (0.96 ± 1.42 to 3.13 ± 2.36 pulses/mi-
nute; p = 0.08). In contrast, saline or L-NAME did not
change the lymphatic pulse in either TNF-Tg or WT
mice. Similarly, L-NIL significantly increased lymph
drainage in TNF-Tg mice compared with saline (73.5 ±
8.9 % vs. 53.2 ± 12.7 % ICG clearance; p < 0.05), while L-
NAME decreased lymphatic drainage in both WT and
TNF-Tg mice. These data indicate that only selective
iNOS inhibition by L-NIL significantly increased lymph-
atic vessel contractions and lymphatic flow in TNF-Tg
mice, but not in WT littermates. The nonspecific NOS in-
hibition by L-NAME significantly decreased ICG clear-
ance in both WT and TNF-Tg mice, consistent with a
critical role for endothelial nitric oxide synthase (eNOS)





Fig. 2 Nitric oxide (NO) from tumor necrosis factor (TNF)-treated lymphatic endothelial cells (LECs) reduces the expression levels of functional
muscle genes in lymphatic smooth muscle cells (LSMCs), which is prevented by a selective inducible nitric oxide synthase (iNOS) inhibitor. a A
schematic cartoon of the coculture model used to assess paracrine effects of NO induced by TNF in LECs on LSMC gene expression. b The effect
of 1 ng/ml TNF on expression levels of functional muscle genes in LSMCs was determined by quantitative polymerase chain reaction (qPCR) and
Western blot analysis. The signal intensity of bands on the Western blot was quantified by densitometry. c LECs were treated with TNF as in (a)
with or without the selective NOS inhibitor aminoguanidine hemisulfate salt (Ami) or Ami alone and then cocultured with LSMCs for another
24 h. The expression levels of functional muscle genes were assessed by qPCR. The fold changes were calculated using phosphate-buffered saline
(PBS)-treated sample values as 1. Values are mean ± standard deviation (SD) of three samples. *p < 0.05 vs. PBS-treated samples. d NO levels in the
conditioned medium of TNF-treated LECs with or without different amounts of Ami or Ami alone were measured by using a Griess method.
Values are mean ± SD of three samples. The experiments were repeated twice with similar results. *p < 0.05 vs. samples without Ami and TNF-treated;
#p < 0.05 vs. TNF-treated samples. NF-κB2 nuclear factor κB2, sMYH smooth muscle myosin heavy chain, SMα smooth muscle actin
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Ferulic acid therapy improves TNF-induced inflammatory
erosive arthritis, which is associated with restored lymphatic
vessel contractions, lymphatic flow, and LSMC gene
expression
Given the toxicity challenges associated with selective
iNOS inhibitors and our interest in understanding the
mechanism of action of traditional Chinese medicines
(TCMs) that have been used successfully to treat pa-
tients with RA who do not respond to disease-modifying
antirheumatic drugs [42–46], we performed a drug
screen in zebrafish to identify TCM-derived small mole-
cules based on their ability to stimulate lymphatic vessel
growth (data not shown). We found ferulic acid, an
Angelica sinensis extract [47] used to treat patients with
vascular disease and arthritis [33, 34, 48, 49], to be our
lead candidate.
To assess the effects of ferulic acid therapy on TNF-Tg
mice with arthritis, we treated a cohort of TNF-Tg mice
for 12 weeks and examined changes in lymphatic flow,
lymphatic contraction frequency, LSMC gene expres-
sion, synovitis, and focal erosions by NIR-ICG imaging,
qPCR, and histology. NIR-ICG imaging demonstrated
that placebo-treated TNF-Tg mice had a significant 30 %
decrease in lymph flow from their lower limbs, as well
as a significant threefold decrease in lymphatic vessel con-
traction frequency, compared with their WT littermates
(p < 0.05). In contrast, ferulic acid therapy restored lymph
flow and lymphatic vessel contraction frequency in TNF-
Tg mice to WT levels (Fig. 5a–e). In vitro coculture stud-
ies demonstrated that ferulic acid increased expression
levels of the muscle functional genes h1-calponinl and
sMYH in LSMCs (Fig. 5f) and completely inhibited TNF-
induced NO production by LECs (Fig. 5g). Ferulic acid did
not restore SMα2 transcript levels in LSMCs, suggesting
that the LEC paracrine factor that downregulates this gene
is not NO. Histologic analyses of ankle tissues from these
mice demonstrated that ferulic acid markedly reduced


















































































Fig. 3 Decreased lymphatic clearance in tumor necrosis factor–transgenic (TNF-Tg) mice is associated with the progression of arthritis. Indocyanine
green ([ICG] 0.1 mg/ml in 6 μl) was injected intradermally into the footpads of 1-, 2.5-, and 5-month-old TNF-Tg mice and their wild-type
(WT) littermates. Lymphatic vessels of the entire leg were examined using near-infrared ICG imaging immediately and at 6 and 24 h post-ICG
administration. The ICG fluorescence signal intensity at the footpads (outlined by the red circles) was recorded. The ICG clearance was calculated.
Shown are a representative ICG signal (a) and the percentage of ICG clearance (b). Values are mean ± standard deviation of four or five mice.
*p < 0.05 vs. WT mice
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by significant decreases in inflammatory tissue area and
osteoclast numbers, as well as significant increases in bone
and cartilage area, compared with placebo controls (Fig. 6).
Thus, ferulic acid amelioration of arthritis is associated
with normalization of draining lymphatic function.
Discussion
Although RA is still broadly considered to be an auto-
immune disease, largely based on diagnostic autoanti-
bodies, a more contemporary view is that RA is a
complex disease syndrome in which variable host and
environmental factors activate several pathogenic
pathways that result in a similar clinical phenotype [50].
One prominent clinical phenotype of RA is sudden-
onset painful synovitis in affected joints, even in patients
responsive to anti-TNF treatment. This is commonly
referred to as arthritic flare, which enigmatically waxes
and wanes over decades of systemic disease without
detectable changes in autoimmunity. One mechanism
we have proposed to account for the development of
arthritic flare involves loss of lymph egress from diseased
joints [7–9]. Consistent with this, we reported lymphatic
draining dysfunction in several animal models of inflam-












































































Fig. 4 Differential effects of selective inducible nitric oxide synthase (iNOS) inhibition vs. total nitric oxide synthase (NOS) inhibition on lymphatic
vessel contractions and lymph drainage in tumor necrosis factor–transgenic (TNF-Tg) mice with flaring arthritis. TNF-Tg mice more than 5 months
old with severe ankle arthritis were used. a TNF-Tg mice (n = 5) were subjected to real-time near-infrared indocyanine green (NIR-ICG) imaging to
quantify the afferent lymphatic pulse before, during, and following a direct injection of saline (a, b) or L-N6-(1-iminoethyl)lysine 5-tetrazole-amide
(L-NIL) (c, d) into the footpad. Representative NIR-ICG images illustrate the lack of ICG lymphatic drainage from the injection site in the footpad
to the region of the popliteal lymph node at 1 h postinjection (a, c). No remarkable changes were observed 9 minutes after saline injection (b).
However, ICG was detected in the primary lymphatic vessel (LV; arrow) and the popliteal lymph node (PLN; arrowhead) within 4 minutes after
L-NIL injection (d). b The lymphatic vessel contraction frequency was determined by assessing pulses in the NIR-ICG signal intensity in the region
of interest (red circles), which was graphed over time during the imaging session. Note the recovery of lymphatic pulses (red arrows) after the
iNOS inhibitor L-NIL (green line) injection, while saline did not affect lymphatic contraction frequency (orange line). c TNF-Tg mice and their
wild-type (WT) littermates (n = 4) underwent pre- and posttreatment NIR-ICG imaging to assess the effects of 6 weeks of saline, L-NIL, and
Nω-nitro-L-arginine methyl ester (L-NAME) on lymphatic vessel contractions (c) and percentage ICG clearance (d). Figure 4c, *P<0.05 between
groups. Figure 4d, *P<0.05 vs WT. #P<0.05 vs. TNF-Tg
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drainage is negatively correlated with the severity of
joint tissue damage [8, 13, 37, 41, 51]. Furthermore, we
demonstrate in the present study that the progression of
ankle arthritis occurs coincident with the loss of lymph-
atic function and lymph flow from the adjacent tissue.
Thus, there is now a large body of experimental evi-
dence to support the theory that arthritis is associated
with lymphatic dysfunction. However, the precise cellu-
lar and molecular mechanisms underlying this lymphatic
dysfunction remain to be elucidated.
It was reported recently that the NO–NOS axis directly
decreases the contractile capacity of LSMCs [22, 23] and
thereby reduces the drainage function of lymphatic vessels.
These findings are based on mouse models of acute inflam-
mation in which the inflammatory responses typically re-
solve spontaneously within 1 week and macrophages are
the major source of iNOS. In contrast to these models, the
inflammation in joints of TNF-Tg mice is long-standing
and progressive, beginning at 2 months after birth, and
worsens without resolving spontaneously as the mice age.
Thus, TNF-Tg mice have features similar to those seen in
patients with RA with uncontrolled active disease.
We initially sought to identify the iNOS-expressing cells
in efferent lymphatic vessels draining affected joints in
TNF-Tg mice that could be responsible for the loss of
lymphatic contractions. We observed vessels draining
inflamed paws. Consistent with published reports, we found
high levels of iNOS expressing Gr-1+ myeloid cells within
the lymphatic vessels. However, because NO has an ex-
tremely short half-life and the numbers of these intralum-
inal myeloid cells are small, we think that they are an
unlikely source of the NO that inhibits LSMCs in the ab-
sence of a major lymphatic endothelial barrier defect. Re-






Fig. 5 Ferulic acid (FLA) rescues impaired lymphatic function in tumor necrosis factor–transgenic (TNF-Tg) mice. Three-month-old TNF-Tg mice
(n = 8/group, comprising 4 females and 4 males) were treated with FLA (20 mg/kg by gavage daily for 12 weeks) or saline and were subjected to
near-infrared indocyanine green imaging (NIR-ICG) imaging. a Chemical structure of FLA. b Representative ICG images show that FLA increased ICG
removal from the ankle area (red circles) 24 h after ICG injection. c Quantitation of percentage of ICG clearance. Values are mean ± standard deviation
(SD) of 16–20 affected legs. d Lymphatic pulses were measured at the region of interest, as shown in Fig. 4. Histogram shows that FLA restored
lymphatic pulses in TNF-Tg mice. e Quantitation of lymphatic pulses/minute. Values are mean ± SD of 9–11 affected legs from 5–7 mice. *p < 0.05 vs.
wild-type (WT) mice, #p < 0.05 vs. TNF-Tg mice. f Lymphatic endothelial cells (LECs) were treated with TNF (as shown in Fig. 2c) with or without FLA for
24 h and then cocultured with lymphatic smooth muscle cells (LSMCs) for another 24 h. The expression levels of functional muscle genes were
determined by quantitative polymerase chain reaction. The fold changes were calculated using the saline-treated sample value as 1. Values are mean
± SD of three samples. g Nitric oxide (NO) levels in the conditioned medium of TNF-treated LECs with or without FLA were measured by a Griess
method as in Fig. 2. Values are mean ± SD of three samples. *p < 0.05 vs. saline-treated group, #p < 0.05 vs. TNF-treated group. h1-Cal h1-calponin,
mRNA messenger RNA, NF-κB2 nuclear factor κB2, SMα smooth muscle actin, sMYH smooth muscle myosin heavy chain
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endothelial cells induces low levels of NO production to
maintain vascular contractile activity [20, 21]. Thus, we
compared eNOS and iNOS expression in LECs in synovial
tissues around TNF-Tg mouse joints and found much
higher levels of iNOS than eNOS (Fig. 1), suggesting that
iNOS may play a more important role than eNOS in NO
production under chronic inflammatory conditions.
Another interesting finding is that very low doses of
TNF (0.1 ng/ml) induced a high level of expression of
iNOS in LECs, indicating that LECs are very sensitive to
iNOS induced locally by inflammatory cytokines. We re-
ported previously that the circulating human TNF levels
in TNF-Tg mice are about 0.1–0.2 ng/ml [36, 52]. Thus,
the dose at which TNF could increase iNOS expression in
LECs is comparable to in vivo TNF levels in TNF-Tg mice.
Our novel findings that TNF directly stimulates iNOS and
NO production in LECs and that this iNOS-induced NO
decreases LSMC gene expression and lymphatic function
in vivo provide a plausible biological mechanism for the
loss of lymphatic vessel contractions and decreased lymph
flow observed during the progression of arthritis.
LECs may be exposed to TNF in vivo by a number of
mechanisms. For example, TNF levels will be increased in
the interstitial fluid draining from inflamed joints when it
passes into collecting lymphatic vessels as well as in soft
tissues generally because of high serum TNF levels in
these mice [14]. Another source of TNF is likely from
macrophages that pass or get trapped in the lymphatic
vessels, as we have described recently [35, 36]. Because in
inflamed joints iNOS can be produced by other cell types,
such as macrophages and synovial cells, it is necessary to
use mice with iNOS knocked out specifically in these and
other cell types to fully determine the role of iNOS pro-
duced by LECs in lymphatic dysfunction in RA. TNF and
other proinflammatory cytokines could also inhibit
LSMCs directly. Thus, multiple factors likely contribute to
the reduced lymphatic drainage in RA.
Our study clearly indicates the contribution of NO from
LECs to inhibition of LSMC function in the setting of TNF
overexpression, which provides experimental evidence for
the use of NOS inhibitors in the treatment of RA. It is im-
portant to note that iNOS is a well-established target for
RA therapy, as the efficacy of two selective inhibitors—L-
NIL [53] and GW274150 [54]—has already been demon-
strated to prevent collagen-induced arthritis. Moreover,





Fig. 6 Ferulic acid (FLA) reduces joint tissue damage in tumor necrosis factor–transgenic (TNF-Tg) mice. Three-month-old TNF-Tg and wild-type
(WT) mice were treated with FLA or saline, as described in Fig. 5. a Representative Alcian Blue/Orange G (ABOG)- and tartrate-resistant acid
phosphatase (TRAP)-stained sections show decreased joint tissue damage, including decreased cartilage (blue arrow) and bone erosion (black
arrow) and TRAP+ osteoclasts in an FLA-treated mouse which has relatively normal joint morphology. Quantitation of inflammatory area (b),
bone area (c), cartilage area (d), and TRAP+ area (e). Values are the mean ± standard deviation of six to eight legs per group. *p < 0.05 vs. WT mice;
#p < 0.05 vs. saline-treated TNF-Tg mice
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clinical trial for early RA, in which the drug showed
a trend toward reduction in synovial thickness (33 %;
p = 0.072) and synovial vascularity (42 %; p = 0.075)
vs. placebo [55]. However, we found that TNF-Tg
mice could not tolerate the published dosing regi-
mens of L-NAME and L-NIL. Because the primary
cause of early death (6–12 months of age) of TNF-Tg
mice is pulmonary hypertension, which is also the
primary toxicity associated with NO inhibitors [56],
we speculate that the combined TNF-induced path-
ology and adverse drug effects lead to unacceptable
side effects that preclude study of potent NOS inhibi-
tors in this model. Thus, we evaluated other known drugs
that have less toxicity. In this study, we chose to investi-
gate TCM derivatives, which have an established highly fa-
vorable safety and tolerability profile in humans.
Following identification of ferulic acid as our lead candi-
date in a zebrafish screen, we demonstrated that treatment
of TNF-Tg mice with this drug significantly (1) increased
lymphatic contraction and transport, (2) blocked TNF-
induced LEC NO production and LSMC inhibition,
and (3) reduced joint inflammation and bone and car-
tilage erosion. Given this initial proof of concept and
that ferulic acid is used to treat patients with vascular dis-
eases and chronic inflammation [33, 34, 48, 49], further
studies are warranted to evaluate this potentially highly
cost-effective therapy for RA. Another approach to redu-
cing toxicity is to generate targeted agents that could be
delivered to joints locally, resulting in enhanced local con-
centrations and reduced systemic toxicity, such as
nanoparticle-embedded drugs, which is currently under
investigation in our laboratory.
Conclusions
We have demonstrated that dysfunction of efferent lymph-
atic vessels from inflamed hind limb joints in TNF-Tg mice
involves TNF-induced iNOS expression and NO production
by LECs, which affects LSMCs and results in decreased
lymphatic vessel contractions and lymph drainage. iNOS in-
hibitors, and especially ferulic acid therapy, ameliorate
TNF-induced arthritis, which is associated with restoration
of lymphatic vessel contractions and drainage. Thus, inhib-
ition of NO production and improvement of lymphatic
vessel draining function together represent a potential
therapeutic strategy for chronic inflammatory arthritis. It
also represents a new mechanism of action for some estab-
lished drugs that have been used to treat patients with in-
flammatory arthritis.
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Additional file 1: Figure S1. HPLC assessment of the purity of the
experimental ferulic acid. The purity of the ferulic acid used in the
experiments used in this study (red line) was determined to be >98 %
homogeneous by HPLC versus a known standard (blue line). (PPTX 45 kb)
Additional file 2: Table S1. Sequences of primers used in real-time
polymerase chain reactions. (PPTX 93 kb)
Additional file 3: Figure S2. Large numbers of iNOS-expressing Gr-1+
monocytes in PLN and efferent lymphatic vessels from arthritic ankles in
TNF-Tg mice. PLNs were harvested from 5-month-old TNF-Tg mice with
frank ankle arthritis and from their nonarthritic WT littermates (n = 5), and
the tissues were processed for fresh frozen IHC using PE-conjugated Gr-1,
FITC-conjugated LYVE-1, and FITC-conjugated iNOS antibodies. DAPI was used
to counterstain nuclei (blue) before fluorescence microscopy. Representative
images (original magnification × 5) of WT (a) and TNF-Tg (b) PLN sections
illustrate the typical increase in size of TNF-Tg PLNs due to increased cellularity
and lymphangiogenesis. c A representative immunofluorescence image
(original magnification × 20) of the boxed region in (b) is shown to illustrate
the prevalence of Gr-1 and iNOS double-positive monocytes within LYVE-1+
lymphatic vessels in TNF-Tg PLN, which were not present in PLN from
nonarthritic WT mice. (PPTX 893 kb)
Additional file 4: Figure S3. Effects of selective (L-NIL) and nonselective
(L-NAME) NOS inhibitors on the lymphatic pulse with WT and TNF-Tg mice.
The number of lymphatic vessel contractions (Pulse #) per minute of ICG filled
lymphatic vessel afferent to the PLN of WT and TNF-Tg mice, pre- and
posttreated with saline, L-NIL, or L-NAME, was quantified from NIR movies as
described in the Methods section. Each data point represents the mean for
an individual mouse in the group with the SEM of the group. (PPTX 61 kb)
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